Alaunos Therapeutics Appoints Dale Curtis Hogue As Interim CEO, Effective Jan. 20 2024; Hogue Will Continue Serving On The Board
Portfolio Pulse from Benzinga Newsdesk
Alaunos Therapeutics has appointed Dale Curtis Hogue as its interim CEO, effective January 20, 2024, according to an SEC filing. Hogue will also continue his role on the company's board.
January 22, 2024 | 9:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Dale Curtis Hogue's appointment as interim CEO of Alaunos Therapeutics may bring fresh leadership perspective, potentially impacting investor sentiment and stock price.
CEO changes can lead to shifts in company strategy and investor confidence. However, as this is an interim position and Hogue is already a board member, the immediate impact may be neutral until his influence on the company's direction becomes clear.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 80